gamma-aminobutyric acid has been researched along with Weight Gain in 33 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Four-hundred and thirty-four patients with partial seizures were randomized to pregabalin, lamotrigine, or placebo as adjunctive therapy for 17 weeks of double-blind treatment." | 9.14 | A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures. ( Barrett, J; Baulac, M; Leon, T; O'Brien, TJ; Whalen, E, 2010) |
| "During phase I, there was a nonsignificant trend toward a greater reduction in seizures with pregabalin versus placebo and lamotrigine." | 9.14 | A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures. ( Barrett, J; Baulac, M; Leon, T; O'Brien, TJ; Whalen, E, 2010) |
| "Pregabalin was demonstrated to be noninferior to lamotrigine in the treatment of refractory partial seizures." | 9.14 | A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures. ( Barrett, J; Baulac, M; Leon, T; O'Brien, TJ; Whalen, E, 2010) |
| "This study assessed the comparative efficacy of pregabalin for refractory partial seizures." | 9.14 | A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures. ( Barrett, J; Baulac, M; Leon, T; O'Brien, TJ; Whalen, E, 2010) |
| "We assessed the efficacy and safety of a flexible-dose pregabalin regimen in patients with diabetic peripheral neuropathy (DPN) or postherpetic neuralgia (PHN) under clinical practice conditions." | 9.13 | Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study. ( Baron, R; Binder, A; Brasser, M; Brunnmüller, U; May, M, 2008) |
| "Pregabalin treatment is associated with a high risk for bodyweight gain which in part depends on total anticonvulsant drug load." | 9.13 | Bodyweight gain under pregabalin therapy in epilepsy: mitigation by counseling patients? ( Elger, CE; Hoffmann, JM; Hoppe, C; Rademacher, M; Schmidt, D, 2008) |
| "Randomized controlled trial on the effects of extended versus standard patient counseling on the risk of bodyweight gain with 3- and 6-month follow-up including a consecutive sample of adult outpatients with epilepsy eligible for pregabalin add-on treatment (N=98)." | 9.13 | Bodyweight gain under pregabalin therapy in epilepsy: mitigation by counseling patients? ( Elger, CE; Hoffmann, JM; Hoppe, C; Rademacher, M; Schmidt, D, 2008) |
| "To evaluate bodyweight gain during pregabalin therapy for epilepsy and the utility of a short counseling program to prevent this side effect." | 9.13 | Bodyweight gain under pregabalin therapy in epilepsy: mitigation by counseling patients? ( Elger, CE; Hoffmann, JM; Hoppe, C; Rademacher, M; Schmidt, D, 2008) |
| "Pregabalin is a novel compound in development for the treatment of anxiety disorders." | 9.11 | Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. ( Davidson, JR; DuBoff, E; Feltner, DE; Futterer, R; Janney, CA; Jefferson, JW; Lydiard, RB; Pande, AC; Phelps, M; Pollack, M; Robinson, P; Slomkowski, M; Stein, MB; Werth, JL, 2004) |
| "The results of this review will assist physicians to better appreciate pregabalin's risk for edema or congestive heart failure and will be pertinent to the thousands of patients worldwide who are administered this medication." | 8.89 | Risk of heart failure and edema associated with the use of pregabalin: a systematic review. ( Chen, M; Ho, JM; Juurlink, DN; Perrier, L; Straus, SE; Tricco, AC, 2013) |
| "Less than half of patients with schizophrenia obtain full response to antipsychotic drugs and, while clozapine represents the treatment of choice for refractory psychosis, a significant number of individuals remain only partially responsive." | 8.89 | Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters. ( Cohn, T; Hahn, MK; Remington, G; Teo, C, 2013) |
| "Olanzapine-induced weight gain is associated with reduced appetite-inhibiting POMC and increased NPY." | 7.78 | Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain. ( Deng, C; Huang, XF; Weston-Green, K, 2012) |
| "Zinc with or without glutamine improved weight gain as compared to untreated, undernourished controls." | 7.76 | Zinc and glutamine improve brain development in suckling mice subjected to early postnatal malnutrition. ( Castro, IC; Costa, SB; Coutinho, BP; de Andrade, GM; de Castro-Costa, CM; Feitosa, GA; Guerrant, RL; Ladd, AA; Ladd, FV; Lima, AA; Magalhães, CE; Oliveira, BB; Oriá, RB; Ribeiro, AA, 2010) |
| "We conclude that glutamine or zinc protects against malnutrition-induced brain developmental impairments." | 7.76 | Zinc and glutamine improve brain development in suckling mice subjected to early postnatal malnutrition. ( Castro, IC; Costa, SB; Coutinho, BP; de Andrade, GM; de Castro-Costa, CM; Feitosa, GA; Guerrant, RL; Ladd, AA; Ladd, FV; Lima, AA; Magalhães, CE; Oliveira, BB; Oriá, RB; Ribeiro, AA, 2010) |
| "The authors reviewed changes in body weight in 44 patients treated with Gabapentin (GPN) for a period of 12 or more months." | 7.69 | Changes in body weight with chronic, high-dose gabapentin therapy. ( DeCerce, J; DeToledo, JC; Ramsay, RE; Toledo, C, 1997) |
| "A case of a patient with medically intractable epilepsy, who developed obstructive sleep apnoea (OSA), and an increase in seizure frequency, as a consequence of weight gain following treatment with vigabatrin is described." | 7.69 | Obstructive sleep apnoea following rapid weight gain secondary to treatment with vigabatrin (Sabril). ( Bird, JM; Lambert, MV, 1997) |
| "In phase II (6 weeks), patients not yet seizure-free were increased to pregabalin 600mg/day or lamotrigine 400mg/day." | 6.75 | A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures. ( Barrett, J; Baulac, M; Leon, T; O'Brien, TJ; Whalen, E, 2010) |
| " The most frequently used dosing regimen involved a starting dose of 150mg/d and dose escalation to 300mg/d after one week (mean: 301mg/d, administered in two doses)." | 6.73 | Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study. ( Baron, R; Binder, A; Brasser, M; Brunnmüller, U; May, M, 2008) |
| "Bodyweight gain was correlated with number of anticonvulsant drugs (r=." | 6.73 | Bodyweight gain under pregabalin therapy in epilepsy: mitigation by counseling patients? ( Elger, CE; Hoffmann, JM; Hoppe, C; Rademacher, M; Schmidt, D, 2008) |
| " The minimum dosage threshold required to induce weight gain in the rat was 0." | 5.38 | Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain. ( Deng, C; Huang, XF; Weston-Green, K, 2012) |
| "Olanzapine-induced weight gain is associated with reduced appetite-inhibiting POMC and increased NPY." | 5.38 | Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain. ( Deng, C; Huang, XF; Weston-Green, K, 2012) |
| "Malnutrition was induced by clustering the litter size from 6-7 pups/dam (nourished control) to 12-14 pups/dam (undernourished control) following birth." | 5.36 | Zinc and glutamine improve brain development in suckling mice subjected to early postnatal malnutrition. ( Castro, IC; Costa, SB; Coutinho, BP; de Andrade, GM; de Castro-Costa, CM; Feitosa, GA; Guerrant, RL; Ladd, AA; Ladd, FV; Lima, AA; Magalhães, CE; Oliveira, BB; Oriá, RB; Ribeiro, AA, 2010) |
| "Pregabalin was demonstrated to be noninferior to lamotrigine in the treatment of refractory partial seizures." | 5.14 | A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures. ( Barrett, J; Baulac, M; Leon, T; O'Brien, TJ; Whalen, E, 2010) |
| "Four-hundred and thirty-four patients with partial seizures were randomized to pregabalin, lamotrigine, or placebo as adjunctive therapy for 17 weeks of double-blind treatment." | 5.14 | A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures. ( Barrett, J; Baulac, M; Leon, T; O'Brien, TJ; Whalen, E, 2010) |
| "During phase I, there was a nonsignificant trend toward a greater reduction in seizures with pregabalin versus placebo and lamotrigine." | 5.14 | A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures. ( Barrett, J; Baulac, M; Leon, T; O'Brien, TJ; Whalen, E, 2010) |
| "This study assessed the comparative efficacy of pregabalin for refractory partial seizures." | 5.14 | A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures. ( Barrett, J; Baulac, M; Leon, T; O'Brien, TJ; Whalen, E, 2010) |
| "We assessed the efficacy and safety of a flexible-dose pregabalin regimen in patients with diabetic peripheral neuropathy (DPN) or postherpetic neuralgia (PHN) under clinical practice conditions." | 5.13 | Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study. ( Baron, R; Binder, A; Brasser, M; Brunnmüller, U; May, M, 2008) |
| "Randomized controlled trial on the effects of extended versus standard patient counseling on the risk of bodyweight gain with 3- and 6-month follow-up including a consecutive sample of adult outpatients with epilepsy eligible for pregabalin add-on treatment (N=98)." | 5.13 | Bodyweight gain under pregabalin therapy in epilepsy: mitigation by counseling patients? ( Elger, CE; Hoffmann, JM; Hoppe, C; Rademacher, M; Schmidt, D, 2008) |
| "To evaluate bodyweight gain during pregabalin therapy for epilepsy and the utility of a short counseling program to prevent this side effect." | 5.13 | Bodyweight gain under pregabalin therapy in epilepsy: mitigation by counseling patients? ( Elger, CE; Hoffmann, JM; Hoppe, C; Rademacher, M; Schmidt, D, 2008) |
| "Pregabalin treatment is associated with a high risk for bodyweight gain which in part depends on total anticonvulsant drug load." | 5.13 | Bodyweight gain under pregabalin therapy in epilepsy: mitigation by counseling patients? ( Elger, CE; Hoffmann, JM; Hoppe, C; Rademacher, M; Schmidt, D, 2008) |
| "Pregabalin is a novel compound in development for the treatment of anxiety disorders." | 5.11 | Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. ( Davidson, JR; DuBoff, E; Feltner, DE; Futterer, R; Janney, CA; Jefferson, JW; Lydiard, RB; Pande, AC; Phelps, M; Pollack, M; Robinson, P; Slomkowski, M; Stein, MB; Werth, JL, 2004) |
| "Less than half of patients with schizophrenia obtain full response to antipsychotic drugs and, while clozapine represents the treatment of choice for refractory psychosis, a significant number of individuals remain only partially responsive." | 4.89 | Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters. ( Cohn, T; Hahn, MK; Remington, G; Teo, C, 2013) |
| "The results of this review will assist physicians to better appreciate pregabalin's risk for edema or congestive heart failure and will be pertinent to the thousands of patients worldwide who are administered this medication." | 4.89 | Risk of heart failure and edema associated with the use of pregabalin: a systematic review. ( Chen, M; Ho, JM; Juurlink, DN; Perrier, L; Straus, SE; Tricco, AC, 2013) |
| "Olanzapine-induced weight gain is associated with reduced appetite-inhibiting POMC and increased NPY." | 3.78 | Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain. ( Deng, C; Huang, XF; Weston-Green, K, 2012) |
| "We showed a preventative effect of intrathecal gabapentin on the development of nerve injury-induced mechanical allodynia and thermal hyperalgesia." | 3.77 | Chronic intrathecal infusion of gabapentin prevents nerve ligation-induced pain in rats. ( Chen, CC; Cheng, JK; Chu, LC; Hung, YC; Lin, CS; Tsaur, ML; Wang, TY, 2011) |
| "We conclude that glutamine or zinc protects against malnutrition-induced brain developmental impairments." | 3.76 | Zinc and glutamine improve brain development in suckling mice subjected to early postnatal malnutrition. ( Castro, IC; Costa, SB; Coutinho, BP; de Andrade, GM; de Castro-Costa, CM; Feitosa, GA; Guerrant, RL; Ladd, AA; Ladd, FV; Lima, AA; Magalhães, CE; Oliveira, BB; Oriá, RB; Ribeiro, AA, 2010) |
| "Zinc with or without glutamine improved weight gain as compared to untreated, undernourished controls." | 3.76 | Zinc and glutamine improve brain development in suckling mice subjected to early postnatal malnutrition. ( Castro, IC; Costa, SB; Coutinho, BP; de Andrade, GM; de Castro-Costa, CM; Feitosa, GA; Guerrant, RL; Ladd, AA; Ladd, FV; Lima, AA; Magalhães, CE; Oliveira, BB; Oriá, RB; Ribeiro, AA, 2010) |
| "A case of a patient with medically intractable epilepsy, who developed obstructive sleep apnoea (OSA), and an increase in seizure frequency, as a consequence of weight gain following treatment with vigabatrin is described." | 3.69 | Obstructive sleep apnoea following rapid weight gain secondary to treatment with vigabatrin (Sabril). ( Bird, JM; Lambert, MV, 1997) |
| "The authors reviewed changes in body weight in 44 patients treated with Gabapentin (GPN) for a period of 12 or more months." | 3.69 | Changes in body weight with chronic, high-dose gabapentin therapy. ( DeCerce, J; DeToledo, JC; Ramsay, RE; Toledo, C, 1997) |
| "In phase II (6 weeks), patients not yet seizure-free were increased to pregabalin 600mg/day or lamotrigine 400mg/day." | 2.75 | A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures. ( Barrett, J; Baulac, M; Leon, T; O'Brien, TJ; Whalen, E, 2010) |
| "Bodyweight gain was correlated with number of anticonvulsant drugs (r=." | 2.73 | Bodyweight gain under pregabalin therapy in epilepsy: mitigation by counseling patients? ( Elger, CE; Hoffmann, JM; Hoppe, C; Rademacher, M; Schmidt, D, 2008) |
| " The most frequently used dosing regimen involved a starting dose of 150mg/d and dose escalation to 300mg/d after one week (mean: 301mg/d, administered in two doses)." | 2.73 | Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study. ( Baron, R; Binder, A; Brasser, M; Brunnmüller, U; May, M, 2008) |
| "Weight gain and alopecia were the most common patient-reported CSEs in this study, and weight gain was the most likely cosmetic side effect to result in dosage adjustment or medication discontinuation." | 1.42 | Cosmetic side effects of antiepileptic drugs in adults with epilepsy. ( Buchsbaum, R; Chen, B; Choi, H; Detyniecki, K; Hirsch, LJ; Javed, A; Kato, K; Legge, A; Moeller, J, 2015) |
| "Hair loss was most commonly reported among patients taking valproic acid (24/270; 8." | 1.42 | Cosmetic side effects of antiepileptic drugs in adults with epilepsy. ( Buchsbaum, R; Chen, B; Choi, H; Detyniecki, K; Hirsch, LJ; Javed, A; Kato, K; Legge, A; Moeller, J, 2015) |
| " Chronic administration decreased glutamate, s-adenosylhomocysteine, and oxidized gluthathione, and increased omega-3 fatty acids." | 1.42 | Central and peripheral metabolic changes induced by gamma-hydroxybutyrate. ( Jimenez, S; Luca, G; Tafti, M; Vaucher, A; Vienne, J, 2015) |
| "Weight gain was the most commonly reported CSE (68/1903, 3." | 1.42 | Cosmetic side effects of antiepileptic drugs in adults with epilepsy. ( Buchsbaum, R; Chen, B; Choi, H; Detyniecki, K; Hirsch, LJ; Javed, A; Kato, K; Legge, A; Moeller, J, 2015) |
| " Cosmetic side effects leading to dosage change or discontinuation occurred most frequently with pregabalin and valproic acid compared with all other AEDs (13." | 1.42 | Cosmetic side effects of antiepileptic drugs in adults with epilepsy. ( Buchsbaum, R; Chen, B; Choi, H; Detyniecki, K; Hirsch, LJ; Javed, A; Kato, K; Legge, A; Moeller, J, 2015) |
| " We compared the overall rate of CSEs and intolerable CSEs (ICSEs-CSEs that led to dosage reduction or discontinuation) between different AEDs in both monotherapy and polytherapy." | 1.42 | Cosmetic side effects of antiepileptic drugs in adults with epilepsy. ( Buchsbaum, R; Chen, B; Choi, H; Detyniecki, K; Hirsch, LJ; Javed, A; Kato, K; Legge, A; Moeller, J, 2015) |
| " Blockade of serotonin (5-HT(3)) receptor signalling in the NTS by either the chronic administration of ondansetron or the genetic inactivation of Tph2 in caudal serotonergic neurons that project to the NTS protects against starvation when AgRP neurons are ablated." | 1.38 | Deciphering a neuronal circuit that mediates appetite. ( Clark, MS; Palmiter, RD; Wu, Q, 2012) |
| " The minimum dosage threshold required to induce weight gain in the rat was 0." | 1.38 | Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain. ( Deng, C; Huang, XF; Weston-Green, K, 2012) |
| "Olanzapine-induced weight gain is associated with reduced appetite-inhibiting POMC and increased NPY." | 1.38 | Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain. ( Deng, C; Huang, XF; Weston-Green, K, 2012) |
| "Gabapentin is an anticonvulsant and adjuvant analgesic." | 1.37 | Chronic intrathecal infusion of gabapentin prevents nerve ligation-induced pain in rats. ( Chen, CC; Cheng, JK; Chu, LC; Hung, YC; Lin, CS; Tsaur, ML; Wang, TY, 2011) |
| "Malnutrition was induced by clustering the litter size from 6-7 pups/dam (nourished control) to 12-14 pups/dam (undernourished control) following birth." | 1.36 | Zinc and glutamine improve brain development in suckling mice subjected to early postnatal malnutrition. ( Castro, IC; Costa, SB; Coutinho, BP; de Andrade, GM; de Castro-Costa, CM; Feitosa, GA; Guerrant, RL; Ladd, AA; Ladd, FV; Lima, AA; Magalhães, CE; Oliveira, BB; Oriá, RB; Ribeiro, AA, 2010) |
| "Gabapentin has been used effectively for neuropathic pain with mild side effects." | 1.35 | Gabapentin and sexual dysfunction: report of two cases. ( Dalal, A; Zhou, L, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (9.09) | 18.2507 |
| 2000's | 11 (33.33) | 29.6817 |
| 2010's | 18 (54.55) | 24.3611 |
| 2020's | 1 (3.03) | 2.80 |
| Authors | Studies |
|---|---|
| Sa, M | 1 |
| Yoo, ES | 1 |
| Koh, W | 1 |
| Park, MG | 1 |
| Jang, HJ | 1 |
| Yang, YR | 1 |
| Bhalla, M | 1 |
| Lee, JH | 1 |
| Lim, J | 1 |
| Won, W | 1 |
| Kwon, J | 1 |
| Kwon, JH | 1 |
| Seong, Y | 1 |
| Kim, B | 1 |
| An, H | 1 |
| Lee, SE | 1 |
| Park, KD | 1 |
| Suh, PG | 1 |
| Sohn, JW | 1 |
| Lee, CJ | 1 |
| Ho, JM | 1 |
| Tricco, AC | 1 |
| Perrier, L | 1 |
| Chen, M | 1 |
| Juurlink, DN | 1 |
| Straus, SE | 1 |
| Chukwu, J | 1 |
| Delanty, N | 1 |
| Webb, D | 1 |
| Cavalleri, GL | 1 |
| Chen, B | 1 |
| Choi, H | 1 |
| Hirsch, LJ | 1 |
| Moeller, J | 1 |
| Javed, A | 1 |
| Kato, K | 1 |
| Legge, A | 1 |
| Buchsbaum, R | 1 |
| Detyniecki, K | 1 |
| Luca, G | 1 |
| Vienne, J | 1 |
| Vaucher, A | 1 |
| Jimenez, S | 1 |
| Tafti, M | 1 |
| Li, XF | 1 |
| Hu, MH | 1 |
| Hanley, BP | 1 |
| Lin, YS | 1 |
| Poston, L | 1 |
| Lightman, SL | 1 |
| O'Byrne, KT | 1 |
| McQuire, C | 1 |
| Hassiotis, A | 1 |
| Harrison, B | 1 |
| Pilling, S | 1 |
| Sandoval-Salazar, C | 1 |
| Ramírez-Emiliano, J | 1 |
| Trejo-Bahena, A | 1 |
| Oviedo-Solís, CI | 1 |
| Solís-Ortiz, MS | 1 |
| Matagne, V | 1 |
| Ehinger, Y | 1 |
| Saidi, L | 1 |
| Borges-Correia, A | 1 |
| Barkats, M | 1 |
| Bartoli, M | 1 |
| Villard, L | 1 |
| Roux, JC | 1 |
| De Smedt, RH | 1 |
| Jaarsma, T | 1 |
| van den Broek, SA | 1 |
| Haaijer-Ruskamp, FM | 1 |
| Zoberi, K | 1 |
| Pollard, CA | 1 |
| Ladd, FV | 1 |
| Ladd, AA | 1 |
| Ribeiro, AA | 1 |
| Costa, SB | 1 |
| Coutinho, BP | 1 |
| Feitosa, GA | 1 |
| de Andrade, GM | 1 |
| de Castro-Costa, CM | 1 |
| Magalhães, CE | 1 |
| Castro, IC | 1 |
| Oliveira, BB | 1 |
| Guerrant, RL | 1 |
| Lima, AA | 1 |
| Oriá, RB | 1 |
| Baulac, M | 1 |
| Leon, T | 1 |
| O'Brien, TJ | 1 |
| Whalen, E | 2 |
| Barrett, J | 1 |
| Chu, LC | 1 |
| Tsaur, ML | 1 |
| Lin, CS | 1 |
| Hung, YC | 1 |
| Wang, TY | 1 |
| Chen, CC | 1 |
| Cheng, JK | 1 |
| Siegel, JA | 1 |
| Park, BS | 1 |
| Raber, J | 1 |
| Wu, Q | 1 |
| Clark, MS | 1 |
| Palmiter, RD | 1 |
| Weston-Green, K | 1 |
| Huang, XF | 1 |
| Deng, C | 1 |
| Cabrera, J | 1 |
| Emir, B | 1 |
| Dills, D | 1 |
| Murphy, TK | 1 |
| Clair, A | 1 |
| Hahn, MK | 1 |
| Cohn, T | 1 |
| Teo, C | 1 |
| Remington, G | 1 |
| Wilton, LV | 1 |
| Shakir, S | 1 |
| Noordmans, AJ | 1 |
| Song, DK | 1 |
| Noordmans, CJ | 1 |
| Garrity-Moses, M | 1 |
| During, MJ | 1 |
| Fitzsimons, HL | 1 |
| Imperiale, MJ | 1 |
| Boulis, NM | 1 |
| Pande, AC | 1 |
| Feltner, DE | 1 |
| Jefferson, JW | 1 |
| Davidson, JR | 1 |
| Pollack, M | 1 |
| Stein, MB | 1 |
| Lydiard, RB | 1 |
| Futterer, R | 1 |
| Robinson, P | 1 |
| Slomkowski, M | 1 |
| DuBoff, E | 1 |
| Phelps, M | 1 |
| Janney, CA | 1 |
| Werth, JL | 1 |
| Nakagawa, T | 1 |
| Yokozawa, T | 1 |
| Kim, HJ | 1 |
| Shibahara, N | 1 |
| Maggioni, F | 1 |
| Ruffatti, S | 1 |
| Dainese, F | 1 |
| Mainardi, F | 1 |
| Zanchin, G | 1 |
| Jastrzebski, Z | 1 |
| Gorinstein, S | 1 |
| Czyzewska-Szafran, H | 1 |
| Leontowicz, H | 1 |
| Leontowicz, M | 1 |
| Trakhtenberg, S | 1 |
| Remiszewska, M | 1 |
| Hoppe, C | 1 |
| Rademacher, M | 1 |
| Hoffmann, JM | 1 |
| Schmidt, D | 1 |
| Elger, CE | 1 |
| Dalal, A | 1 |
| Zhou, L | 1 |
| Baron, R | 1 |
| Brunnmüller, U | 1 |
| Brasser, M | 1 |
| May, M | 1 |
| Binder, A | 1 |
| Gidal, BE | 1 |
| Maly, MM | 1 |
| Nemire, RE | 1 |
| Haley, K | 1 |
| Lambert, MV | 1 |
| Bird, JM | 1 |
| DeToledo, JC | 1 |
| Toledo, C | 1 |
| DeCerce, J | 1 |
| Ramsay, RE | 1 |
| Serkova, N | 1 |
| Jacobsen, W | 1 |
| Niemann, CU | 1 |
| Litt, L | 1 |
| Benet, LZ | 1 |
| Leibfritz, D | 1 |
| Christians, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Role of the Gut Microbiome as Determinant of Depression in Multiple Sclerosis Subjects[NCT05808101] | 120 participants (Anticipated) | Observational | 2022-01-27 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for gamma-aminobutyric acid and Weight Gain
| Article | Year |
|---|---|
Risk of heart failure and edema associated with the use of pregabalin: a systematic review.
Topics: Edema; gamma-Aminobutyric Acid; Heart Failure; Humans; Outcome Assessment, Health Care; Pregabalin; | 2013 |
Weight change, genetics and antiepileptic drugs.
Topics: Animals; Anticonvulsants; Epilepsy; gamma-Aminobutyric Acid; Genetic Predisposition to Disease; Huma | 2014 |
Pharmacological interventions for challenging behaviour in children with intellectual disabilities: a systematic review and meta-analysis.
Topics: Adaptation, Psychological; Adolescent; Anticonvulsants; Antioxidants; Antipsychotic Agents; Child; C | 2015 |
Characterizing and understanding body weight patterns in patients treated with pregabalin.
Topics: Adult; Aged; Anticonvulsants; Body Weight; Comprehension; Diabetic Neuropathies; Epilepsies, Partial | 2012 |
Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters.
Topics: Anticonvulsants; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Fructose; gamma-Aminobu | 2013 |
5 trials available for gamma-aminobutyric acid and Weight Gain
| Article | Year |
|---|---|
A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dizziness; Double-Blind Method; Epilepsies, Partial; Fem | 2010 |
Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety; Double-Blind Method; Female; gamma-Aminobutyr | 2004 |
Weight variations in the prophylactic therapy of primary headaches: 6-month follow-up.
Topics: Adrenergic beta-Antagonists; Adult; Amines; Amitriptyline; Analgesics, Non-Narcotic; Anticonvulsants | 2005 |
Bodyweight gain under pregabalin therapy in epilepsy: mitigation by counseling patients?
Topics: Adult; Anticonvulsants; Body Mass Index; Counseling; Diet; Epilepsy; Exercise; Female; Follow-Up Stu | 2008 |
Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study.
Topics: Adolescent; Adult; Aged; Anxiety; Diabetic Neuropathies; Dizziness; Dose-Response Relationship, Drug | 2008 |
23 other studies available for gamma-aminobutyric acid and Weight Gain
| Article | Year |
|---|---|
Hypothalamic GABRA5-positive neurons control obesity via astrocytic GABA.
Topics: Animals; Astrocytes; Disease Models, Animal; gamma-Aminobutyric Acid; Male; Mice; Monoamine Oxidase; | 2023 |
Cosmetic side effects of antiepileptic drugs in adults with epilepsy.
Topics: Acne Vulgaris; Adult; Alopecia; Anticonvulsants; Epilepsy; Female; gamma-Aminobutyric Acid; Gingival | 2015 |
Central and peripheral metabolic changes induced by gamma-hydroxybutyrate.
Topics: Alcohol Oxidoreductases; Animals; Body Composition; Cell Respiration; Cerebral Cortex; Corticosteron | 2015 |
Pregabalin: major weight gain.
Topics: Analgesics; Anti-Anxiety Agents; Anticonvulsants; Female; gamma-Aminobutyric Acid; Humans; Male; Mid | 2015 |
The Posterodorsal Medial Amygdala Regulates the Timing of Puberty Onset in Female Rats.
Topics: Amygdala; Animals; Bicuculline; Estrous Cycle; Female; GABA-A Receptor Antagonists; gamma-Aminobutyr | 2015 |
A high-fat diet decreases GABA concentration in the frontal cortex and hippocampus of rats.
Topics: Animals; Blood Glucose; Body Weight; Diet, High-Fat; Feeding Behavior; Frontal Lobe; gamma-Aminobuty | 2016 |
A codon-optimized Mecp2 transgene corrects breathing deficits and improves survival in a mouse model of Rett syndrome.
Topics: Amines; Animals; Apnea; Codon; Cyclohexanecarboxylic Acids; Dependovirus; Disease Models, Animal; Di | 2017 |
Decompensation of chronic heart failure associated with pregabalin in a 73-year-old patient with postherpetic neuralgia: a case report.
Topics: Aged; Anticonvulsants; Bumetanide; Chronic Disease; gamma-Aminobutyric Acid; Heart Failure; Herpes Z | 2008 |
Treating anxiety without SSRIs.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Anticonvulsants; Anxiety Disorders; Benzodiazepines; Comorbi | 2010 |
Zinc and glutamine improve brain development in suckling mice subjected to early postnatal malnutrition.
Topics: Animals; Animals, Newborn; Behavior, Animal; Brain; Dietary Supplements; Drug Therapy, Combination; | 2010 |
Chronic intrathecal infusion of gabapentin prevents nerve ligation-induced pain in rats.
Topics: Amines; Analgesics, Non-Narcotic; Animals; Cauda Equina; Cyclohexanecarboxylic Acids; Disease Models | 2011 |
Methamphetamine exposure during brain development alters the brain acetylcholine system in adolescent mice.
Topics: Acetylcholine; Animals; Axons; Brain; Cell Count; Choline O-Acetyltransferase; Densitometry; DNA-Bin | 2011 |
Deciphering a neuronal circuit that mediates appetite.
Topics: Agouti-Related Protein; Animals; Appetite; Body Weight; Feeding Behavior; Female; gamma-Aminobutyric | 2012 |
Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain.
Topics: Animals; Antipsychotic Agents; Appetite Regulation; Arcuate Nucleus of Hypothalamus; Base Sequence; | 2012 |
A postmarketing surveillance study of gabapentin as add-on therapy for 3,100 patients in England.
Topics: Acetates; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 an | 2002 |
Adeno-associated viral glutamate decarboxylase expression in the lateral nucleus of the rat hypothalamus reduces feeding behavior.
Topics: Adenoviridae; Animals; Eating; Feeding Behavior; gamma-Aminobutyric Acid; Gene Targeting; Gene Trans | 2004 |
Protective effects of gamma-aminobutyric acid in rats with streptozotocin-induced diabetes.
Topics: Animals; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Experimental; gamma-Aminobutyric | 2005 |
The effect of short-term lyophilized beer consumption on established hypertension in rats.
Topics: Animals; Antihypertensive Agents; Antioxidants; Beer; Freeze Drying; gamma-Aminobutyric Acid; Hypert | 2007 |
Gabapentin and sexual dysfunction: report of two cases.
Topics: Adolescent; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2008 |
Weight gain and gabapentin therapy.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Ami | 1995 |
Obstructive sleep apnoea following rapid weight gain secondary to treatment with vigabatrin (Sabril).
Topics: Adult; Anticonvulsants; Epilepsy; gamma-Aminobutyric Acid; Humans; Male; Seizures; Sleep Apnea Syndr | 1997 |
Changes in body weight with chronic, high-dose gabapentin therapy.
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Body Weight; Cyclohexanecarboxylic Acids; Fema | 1997 |
Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain.
Topics: Animals; Aspartic Acid; Body Weight; Brain; Cyclosporine; Drug Synergism; Everolimus; gamma-Aminobut | 2001 |